Cardiff Oncology, Inc.
As of Oct 22, 2026, Cardiff Oncology is in Stage 1, the basing phase, now in week 4 (since Sep 29, 2026). It closed at $0.93, 71.0% below its 52-week high and below its 200-day average, which is falling.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CRDF early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CRDF among Biotechnology388th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …388 | CRDF | Stage 1 · wk 4 | 19 | −29.0% |
Cardiff Oncology: quick answers
What stage is Cardiff Oncology in?
As of Oct 22, 2026, Cardiff Oncology (CRDF) is in Stage 1, the basing phase. It entered Stage 1 on Sep 29, 2026 and is in week 4. What the four stages mean
Is Cardiff Oncology in an uptrend?
Not yet. Cardiff Oncology is in Stage 1, a base that can come before an uptrend. It trades 38.0% below its 200-day average, which is falling.
How far is Cardiff Oncology from its 52-week high?
Cardiff Oncology closed at $0.93 on Oct 22, 2026, 71.0% below its 52-week high of $3.21. Its 52-week low is $0.81.
How has Cardiff Oncology performed over the past year?
As of Oct 22, 2026, Cardiff Oncology is down 58.3% over the past year and down 65.0% so far in 2026.
Which sector and industry is Cardiff Oncology in?
Cardiff Oncology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.